[Skip to Navigation]
Research Letter
January 6, 2021

Burden of Ocular Comorbidities in Patients With Hidradenitis Suppurativa

Author Affiliations
  • 1Department of Surgery, University of Maryland, Baltimore
  • 2Dermatology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
  • 3Department of Mathematics and Statistics, Laboratory for Industrial and Applied Mathematics (LIAM), York University, Toronto, Ontario, Canada
  • 4Department of Medicine B and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel
  • 5Padeh and Ziv Hospitals, Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel
  • 6Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
  • 7Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
JAMA Dermatol. 2021;157(2):226-227. doi:10.1001/jamadermatol.2020.5087

Hidradenitis suppurativa (HS) is a chronic systemic inflammatory disorder of the terminal follicular epithelium in the apocrine gland–bearing skin. Clinically, it is characterized by lesions, including comedones, papules, pustules, nodules, and fistulas, that are mainly concentrated in axillae, perineal, and submammary areas.1

Other autoimmune diseases are associated with ocular comorbidities; however, there is a paucity of data on ocular comorbidities in HS.1-4 In this article, we aim to quantify the burden of ocular comorbidities in patients with HS.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words